Medicare administrator, Chiquita Brooks-LaSure, said in a statement Thursday the program will begin paying for the drug now that it has full FDA approval. But the government is also setting extra requirements, including enrollment in a federal registry to track the drug’s real-world safety and effectiveness.
Some Medicare patients could be responsible for paying the standard 20% of the cost of Leqembi, though the amount will vary depending on their plans and other coverage details. Doctors need to confirm that patients have the brain plaque targeted by Leqembi before prescribing it. Nurses need to be trained to administer the drug and patients must be monitored with repeated brain scans to check for swelling or bleeding. The imaging and administration servicesEisai has told investors that about 100,000 Americans could be diagnosed and eligible to receive Leqembi by 2026. The drug is co-marketed with Cambridge, Massachusetts-based Biogen.
Source: Healthcare Press (healthcarepress.net)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Source: CNBC - 🏆 12. / 72 Read more »
FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverageDespite Medicare coverage, drug may remain out of reach for many patients, policy experts say
Source: MarketWatch - 🏆 3. / 97 Read more »
Alzheimer’s drug Leqembi granted full FDA approval and that means Medicare will pay for itU.S. officials have granted full approval to a closely watched Alzheimer’s drug for patients with early stages of the disease.
Source: FOX29philly - 🏆 570. / 51 Read more »
FDA Approves Leqembi, Extending Alzheimer’s Treatment to More PatientsThe FDA granted full approval to Alzheimer's drug Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry
Source: WSJ - 🏆 98. / 63 Read more »
Alzheimer’s drug Leqembi granted full FDA approvalUPDATE: U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
Source: WTVYNews4 - 🏆 590. / 51 Read more »
Alzheimer’s drug Leqembi receives full FDA approvalThe Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer’s disease. It’s the first medicine that’s been convincingly shown to modestly slow Alzheimer’s cognitive decline.
Source: chicagotribune - 🏆 8. / 91 Read more »